Maxigen Biotech Osake

Maxigen Biotech EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Maxigen Biotech (1783.TW) 15.8.2026 päivämäärällä on 261,04 M TWD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli 194,72 M TWD — muutos 34,06 % (korkeampi).

EBITDA

261,04 MTWD

YoY

34,06%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Maxigen Biotech on 2026 261,04 M TWD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Maxigen Biotech oli 2025 194,72 M TWD. Se laskee 34,06% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Maxigen Biotech Osakeanalyysi

Mitä Maxigen Biotech tekee? Maxigen Biotech Inc is a biotechnology company that was founded in 2000. The company, based in San Francisco, California, specializes in the development and production of biotechnological products and solutions. The company's goal is to lead in the biotechnology industry and have a positive impact on the health and well-being of people. To achieve its goals, the company has specialized in four business areas. The first business area is the research and development of new biotechnological products. The company has a team of scientists who work continuously on new innovative technologies and products. The company has already brought several products to market that have been very successful in the biotechnology industry. The second business area is the production of biotechnological products. The company has its own production facility equipped with state-of-the-art technologies. Here, the company's products are manufactured and delivered to customers worldwide. The third business area is the distribution of biotechnological products. The company has built a large distribution network to distribute its products in different parts of the world. The company works closely with pharmacies, laboratories, and hospitals to ensure that its products are made accessible to people. The fourth business area is the application of biotechnological products. The company works closely with doctors and healthcare facilities to ensure that its products are used in medical practice. The company is committed to using its products to improve the health and well-being of people worldwide. Maxigen Biotech Inc has introduced some remarkable products to the market in its history. One of the company's most important products is a highly effective antibiotic used to fight bacterial infections. The company has also developed a medication for the treatment of hypertension that is in high demand worldwide. Additionally, the company has developed a range of products for the treatment of cancer and other serious illnesses. The company has also made a significant contribution to public health. The company has developed technology to lower cholesterol levels in the blood, which can help prevent cardiovascular diseases. The company has also worked on the development of vaccines against infectious diseases that are still prevalent in some regions of the world. Maxigen Biotech Inc has received numerous awards and recognition in its history. The company is known for its innovation and high quality in the production of its products. The company is an example of how the biotechnology industry can contribute to improving the health and well-being of people worldwide. In summary, Maxigen Biotech Inc is a biotechnology company that specializes in the development and production of biotechnological products and solutions. The company has specialized in four business areas: research and development of new products, production of biotechnological products, distribution of biotechnological products, and application of biotechnological products. The company has introduced some remarkable products to the market in its history and has made a significant contribution to public health. The company has received numerous awards and recognition and is an example of excellence in the biotechnology industry. Maxigen Biotech on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Maxigen Biotech osakkeesta

Yhtiön Maxigen Biotech EBITDA (Tulos ennen korkoja, veroja ja poistoja) on 261,04 M TWD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Maxigen Biotech muuttui arvosta 194,72 M TWD arvoon 261,04 M TWD, mikä edustaa 34,06 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Maxigen Biotech:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n TWD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Maxigen Biotech historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Maxigen Biotech

Kaikki tunnusluvut — Maxigen Biotech